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INTRODUCTION
Recurrence of malignant disease is the most signiﬁcant
problem following autologous hematopoietic cell trans-
plantation (HCT), even in studies that demonstrate an
unequivocal benefit for this therapy [1,2]. Alterations in
transplantation preparative regimens alone are unlikely to
abolish this risk. In allogeneic HCT, immune system manip-
ulation through donor leukocyte infusions is effective in the
treatment of relapsed chronic myelogenous leukemia
(CML) and acute myelogenous leukemia (AML) [3,4]. This
graft-versus-leukemia (GVL) effect is the basis for nonmye-
loablative allogeneic stem cell transplantation [5,6].
Immune system augmentation through autologous
adoptive immunotherapy has been used to treat patients
with metastatic renal cell carcinoma and malignant
melanoma. The use of lymphokine-activated killer (LAK)
cells is one form of this therapy. These cells may be gener-
ated by incubating patients’ peripheral blood lymphocytes
(PBL) ex vivo with interleukin (IL)-2. LAK cells lyse multi-
ple tumor cell lines without prior sensitization through a
mechanism that is not major histocompatibility complex
(MHC) restricted. Autologous LAK cells coadministered
with high-dose systemic IL-2 may produce tumor regres-
sion in some patients with advanced cancers [7-9]. Poor ex
vivo expansion of LAK cells, marginal antitumor activity,
the need for systemic IL-2, and potentially life-threatening
toxicity limit the usefulness of this form of adoptive
immunotherapy [9].
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ABSTRACT
Immunotherapy may potentially improve the outcome of autologous hematopoietic cell transplantation (HCT).
Poor effector cell proliferation and marginal antitumor activity limit attempts to use immunotherapy. We have char-
acterized the ex vivo expansion, up to 1000-fold, of CD3+CD56+ lymphocytes from the peripheral blood lymphocytes
(PBL) of healthy donors. Expanded cells termed cytokine-induced killer (CIK) cells induce non–major histocompat-
ibility complex–restricted lysis of tumor cells and demonstrate cytolytic activity superior to lymphokine-activated
killer cells without the requirement of interleukin (IL)-2 treatment in vivo. To determine whether cytolytic cells
could be expanded from patient material, we evaluated samples of peripheral blood progenitor cells (PBPCs) from
25 patients undergoing autologous HCT. The PBPCs were expanded by priming with interferon-γ followed by anti-
CD3 monoclonal antibody and IL-2 the next day. Fluorescence-activated cell sorting analysis was performed on days
0, 15, 21, and 28 of cell culture. The median T-cell content rose from 15.3% (range, 1.1% to 89.7%) on day 0 to
97.2% (range, 83.6% to 99.5%) by day 15. By day 21, T cells expanded 21.8-fold (range, 1.7- to 420.0-fold) and
CD3+CD56+ cells expanded 44.8-fold (range, 5.1- to 747.0-fold). CIK cells were used as effector cells against B-cell
lymphoma targets (OCI-Ly8) with a median of 24% (range, 3% to 67%) and 42% (range, 6% to 96%) specific lysis
of target cells on days 21 and 28, respectively. CIK cells derived from PBL of 2 additional patients with acute myel-
ogenous leukemia demonstrated 39% and 78% specific lysis of OCI-Ly8 and 26% and 58% specific lysis of autologous
leukemic blasts at an effector:target ratio of 40:1. CIK cells may be expanded from granulocyte colony-stimulating
factor–mobilized PBPCs of patients undergoing autologous HCT. CIK cells may provide a potent tool for use in
posttransplantation adoptive immunotherapy.
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We have characterized the ex vivo expansion of
CD3+CD56+ lymphocytes [10-12]. After initial priming with
interferon (IFN)-γ and incubation with anti-CD3 monoclo-
nal antibodies (MoAbs) followed by IL-2 one day later,
CD3+CD56+ cells may be expanded up to 1000-fold from the
PBL of healthy donors. We have termed these cells cytokine-
induced killer (CIK) cells [13,14]. The CD3+CD56+ cells are
principally expanded from CD3+CD56– progenitors with
more than 50% of the CD3+CD4–CD8– subpopulation gain-
ing CD56 expression in culture [13]. CIK cells demonstrate
non-MHC–restricted cytotoxicity in vitro against multiple
tumor targets without prior sensitization. Target cell killing
is accomplished through either granzyme-perforin or fas-
mediated mechanisms [15 and (E.G.H., J.C.A., P.H. Lu,
R.S.N., unpublished data, 2001)] and is not blocked by
MoAbs directed against CD3, HLA class I, or HLA class II.
MoAbs against LFA-1 or the counter-receptor ICAM-1
block cytotoxicity against sensitive tumor targets (E.G.H.,
J.C.A., P.H. Lu, unpublished data, 2000). In colony-forming
unit granulocyte-macrophage assays, however, CIK cells do
not demonstrate significant toxicity against bone marrow
progenitor cells [16]. In models of severe combined immun-
odeﬁciency (SCID) mice engrafted with human non-Hodgk-
in’s lymphoma (NHL), CML, and solid tumors, CIK cells
demonstrate signiﬁcant in vivo antitumor effects without the
need for systemic coadministration of IL-2 [13,17,18].
Because CIK cells expand readily and are biologically
active without coadministration of IL-2, they may provide a
potent and less toxic alternative to LAK cells for adoptive
immunotherapy. The post–autologous HCT period may
provide an ideal opportunity to exploit autologous GVL
while the patient is in a minimal disease state [19]. In this
study we characterize the expansion of CIK cells from the
mobilized peripheral blood progenitor cells (PBPCs) of
patients undergoing autologous HCT for a variety of
malignancies and characterize the cytolytic activity of the
expanded CIK cells against a NHL cell line and autologous
leukemic blasts.
MATERIALS AND METHODS
Patient Population and Collection of PBPCs
PBPC samples were obtained from patients undergoing
apheresis in preparation for autologous HCT. Treatment pro-
tocols were approved by the Human Subjects Committee of
the Stanford University Medical Center Institutional Review
Board and informed consent was obtained prior to apheresis.
Patients with NHL, multiple myeloma, acute lym-
phoblastic leukemia, and Hodgkin’s disease (HD) underwent
apheresis upon white blood cell recovery greater than
1000/mm3 following chemotherapy and ﬁlgrastim mobiliza-
tion (10 µg/kg per day of granulocyte colony-stimulating
factor [G-CSF] administered subcutaneously). Patients with
breast cancer, ovarian cancer, testicular cancer, or central
nervous system malignancy underwent apheresis following
5 days of subcutaneous administration of G-CSF (10 µg/kg
per day) without the use of specific mobilizing chemo-
therapy. PBPCs were collected over 4 hours using the Cobe
Spectra blood cell separator (Cobe; Blood Component
Technology, Lakewood, CO) and a 1- to 2-mL cell aliquot
was obtained for ex vivo studies.
CIK Culture Conditions
PBPC aliquots were diluted at a ratio of approximately
1:10 with Dulbecco’s phosphate buffered saline (PBS; Gibco
BRL, Grand Island, NY) and separated by Ficoll-Hypaque
centrifugation (Lymphoprep; Robbins Scientiﬁc, Sunnyvale,
CA). The washed cells were counted and placed in complete
medium consisting of RPMI-1640 (Gibco), 10% fetal calf
serum (Hyclone, Logan, UT), 2 mmol/L L-glutamine,
100 U/mL penicillin, 100 µg/mL streptomycin, and 50 nmol/L
2-mercaptoethanol. Cell cultures were maintained at a den-
sity of approximately 1 to 3 × 106 cells/mL.
On day 0, CIK cultures were primed with 1000 U/mL
IFN-γ (Genentech, South San Francisco, CA). On day 1,
25 ng/mL of the anti-CD3 MoAb OKT3 (Murimab; Ortho
Biotech, Raritan, NJ) and 300 U/mL recombinant human
IL-2 (Chiron, Emeryville, CA) were added to the culture.
CIK cultures were incubated in a humidiﬁed atmosphere of
5% CO2 at 37ºC, counted, and fed with complete medium
every 3 days. Cultures were re-treated with 300 U/mL of IL-2
every 6 days.
Fluorescence-Activated Cell Sorter Analysis of
Surface Markers
PBPC specimens were analyzed by ﬂuorescence-activated
cell sorting (FACS) following Ficoll-Hypaque preparation.
CIK cultures were subsequently reanalyzed on days 14, 21,
and 28. Cell aliquots were washed in PBS prior to staining. A
previously described 1-stage staining procedure was per-
formed using ﬂuorescein isothiocyanate (FITC)–conjugated
MoAb directed against CD3 and phycoerythrin (PE)-
conjugated MoAb directed against CD56 (Becton Dickinson,
San Jose, CA) [13]. Staining was also performed with isotype
controls (Becton Dickinson) and 5 × 103 cells analyzed with a
Coulter Epics Proﬁle II (Coulter, Hialeah, FL).
51Cr Release Assays of Target Cell Cytolysis
The human B-cell lymphoma cell line, OCI-Ly8, was
grown in complete medium in a humidified incubator at
37ºC in 5% CO2. OCI-Ly8 cells were labeled for 2 hours
with 200 to 400 µCi 51Cr (DuPont-New England Nuclear,
Boston, MA). The OCI-Ly8 cells were then washed 3 times
with PBS and a total of 2 × 104 cells/well were pipetted into
96-well plates (Costar, Cambridge, MA). Washed CIK cells
were added at effector:target ratios of 1:1, 2:1, 5:1, 10:1,
20:1, and 40:1. Labeled targets lysed with NP40 provided a
measure of maximum release, and target cells incubated in
the medium alone indicated minimum release. The plates
were incubated for 4 hours at 37ºC, then centrifuged for
5 minutes, and an aliquot of supernatant was removed from
each well for analysis in a gamma counter. All ratios were
performed in triplicate and mean values ± SD were used to
calculate speciﬁc lysis by the following equation:
Test Release – Minimum Release   
× 100%Maximum – Minimum Release
Assessment of Patient CIK Cell Killing Versus
Autologous AML Cells
Discarded peripheral blood cells were obtained from a
patient (patient 1) with AML who underwent therapeutic
leukopheresis for life-threatening hyperleukocytosis.
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Leukopheresed cells were cryopreserved in liquid nitrogen
using 20% plasma and 10% dimethylsulfoxide (DMSO;
Research Industries, Salt Lake City, UT) as a cryoprotec-
tant. The cryopreserved cells were rapidly thawed in a 37ºC
water bath and placed either in complete medium (for cells
to be subsequently placed in CIK cell culture) or in com-
plete medium containing100 ng/mL stem cell factor (SCF;
Immunex, Seattle, WA), 100 ng/mL IL-3 (Immunex, Seattle,
WA), 50 ng/mL granulocyte-macrophage colony–stimulating
factor (GM-CSF) (Immunex, Seattle, WA), and 100 ng/mL
G-CSF (Amgen, Thousand Oaks, CA) (for cells intended to
be used as autologous tumor targets). The cells were incu-
bated for 24 hours and washed with PBS, and cellular
debris was removed with Ficoll-Hypaque separation. The
washed cells were either used immediately as targets for
autologous CIK cells in 51Cr release assays or expanded
under CIK culture conditions.
After informed consent was obtained, peripheral blood
was obtained from a second patient (patient 2) with
relapsed AML. After Ficoll-Hypaque separation, the cells
were cultured in complete medium either containing the
cytokine cocktail detailed above or under CIK cell culture
conditions. The cultures were re-treated with cytokines
every 6 to 7 days.
CIK cells, expanded from either cryopreserved leuko-
pheresed cells or the peripheral blood of these patients,
were analyzed by FACS to determine percentages of
CD3+CD56+ cells. Leukemic target cells were analyzed
separately with either CD33-PE (patient 1) or CD14-
FITC/CD13-PE (patient 2) to confirm target cell pheno-
type prior to use in cytolytic assays. 51Cr cytotoxicity assays
were performed using CIK cells and autologous blasts as
targets using the procedure detailed above.
RESULTS
Patient Characteristics
PBPCs were cultured from 25 patients undergoing cell
collection prior to planned high-dose therapy. Patient
characteristics for this group are detailed in the Table. All
of the patients received chemotherapy prior to considera-
tion of high-dose therapy. Seven patients (1 with an oligo-
dendroglioma and 6 with hematologic malignancies) also
previously received radiotherapy. All of the patients with
solid tumors were mobilized with G-CSF alone prior to
apheresis, and all but 1 of the patients with hematologic
malignancies (a patient with HD) were mobilized with
chemotherapy and G-CSF prior to apheresis. All of the
patients, except a patient with progressive NHL, had
responsive disease at the time of PBPC collection. One
patient with an oligodendroglioma did not proceed to
transplantation following PBPC collection.
T-Cell and CD3+CD56+-Cell Expansion in Culture
T cells were quantified by anti-CD3 MoAb staining.
Over the course of the culture incubation, the PBPCs
demonstrated a phenotypic change with T cells becoming
the predominant cell type by day 15. Due to poor cell yields
following Ficoll-Hypaque separation, PBPCs from 2 patients
with hematologic malignancies were not assessed for pheno-
type prior to cell culture. The median starting T-cell per-
centage was 15.3% (range, 1.1% to 89.7%). By day 15 of
culture, the T-cell percentage (21 evaluable samples) had
risen to a median of 97.2% (range, 83.6% to 99.5%). After
28 days in culture, the median T-cell percentage (19 evalu-
able samples) was 95.5% (range, 35.4% to 99.5%).
Numerical expansion of CD3+CD56– T cells and
CD3+CD56+ cells is demonstrated in Figure 1. Following
21 days in culture, the PBPCs (18 evaluable samples)
demonstrated a 21.8-fold median expansion in T-cell num-
ber (range, 1.7- to 420.0-fold). This group exhibited a
median 44.8-fold expansion in CD3+CD56+ cells (range,
5.1- to 747.0-fold). Following 28 days in culture (19 evalu-
able samples), there was a 20.6-fold median T-cell expansion
(range, 1.1- to 444.5-fold) and a 74.9-fold expansion in
CD3+CD56+ cells (range, 6.2- to 391.0-fold).
Cytotoxic Activity
CIK cells were assessed for cytolytic activity against the
B-cell NHL target cell line, OCI-Ly8. Figure 2 demon-
strates the cytolytic activity for CIK cells following 21 and
28 days in culture. All results represent cytolytic activity at
an effector:target ratio of 40:1. The CIK cells demonstrated
an overall median of 24% speciﬁc lysis (range, 3% to 67%)
of OCI-Ly8 following 21 days in culture (21 evaluable sam-
ples) and a median of 42% (range, 6% to 96%) following
28 days (20 evaluable samples) in culture.
Characteristics of 25 Patients Who Underwent Autologous Hematopoietic Cell
Transplantation Receiving Expanded PBPCs*
Gender
Female 14
Male 11
Age, y 47 (24-68)
Diagnosis
Non-Hodgkin’s lymphoma 6
Multiple myeloma 4
Acute lymphoblastic leukemia 1
Hodgkin’s disease 1
Chronic lymphocytic leukemia 1
Breast cancer 9
Germ cell cancer 1
Ovarian cancer 1
Oligodendroglioma 1
PBPC mobilization
G-CSF alone 13
G-CSF + chemotherapy 12
DHAP 1
VP-16 3
VP-16/ara-C 1
VP-16/cyclophosphamide 4
Cyclophosphamide 3
Status at transplantation
Complete response 13
Partial response 10
Progressive disease 1
Transplantation not performed 1
*Data are median (range) or n. PBPC indicates peripheral blood
progenitor cell; G-CSF, granulocyte colony-stimulating factor; DHAP
indicates dexamethasone, high-dose cytarabine, and cisplatin; VP-16,
etoposide; ara-C, cytosine arabinoside.
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Cytolysis Against Autologous Tumor Targets
CIK cells were expanded from the PBL of 2 patients
with AML. CIK cells derived from the leukopheresed prod-
uct of patient 1 demonstrated an increase in CD3+CD56+
cells from 1.5% on day 0 to 22.9% by day 28 of culture. On
day 0, PBL from patient 2 contained 1.5% CD3+CD56+
cells as well as 16.8% CD13+ and 29.5% CD13+CD14+ cells
(the documented blast phenotype). Following 44 days of
incubation, the CD3+CD56+ cells increased to 42.3% of the
cell population and the CD13+ and CD13+CD14+ decreased
to 0.9% and 0.3%, respectively (Figure 3). Cytogenetic
studies performed on day 37 of CIK culture demonstrated
that the chromosome 7 abnormalities that had been present
in the blasts at the time of diagnosis were not detectable in
any of the 6 analyzable metaphases. 
These CIK cells were incubated with both autologous
blasts and OCI-Ly8 targets. Figure 4 demonstrates the spe-
ciﬁc lysis against each of these targets. At an effector:target
cell ratio of 40:1, CIK cells from the 2 patients demon-
strated 78% (patient 1) and 39% (patient 2) speciﬁc lysis of
OCI-Ly8 and 58% (patient 1) and 26% (patient 2) speciﬁc
lysis of autologous blasts.
Figure 1. Median overall, T-cell, and CD3+CD56+-cell expansion in vitro, based on evaluable samples on days 0, 15, 21, and 28.
Figure 2. Speciﬁc lysis of the target B-cell lymphoma cell line, OCI-Ly8, by cytokine-induced killer cells derived from peripheral blood progenitor
cell products. Experiments were performed in triplicate and the mean value for each patient is indicated. Median speciﬁc lysis was 24% (range, 3%
to 67%) and 42% (range, 6% to 96%) on days 21 and 28, respectively. 
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DISCUSSION
Previous attempts at adoptive immunotherapy in
patients with advanced malignancies have resulted in limited
efﬁcacy with less than 50% of patients achieving a response
and less than 10% of patients having a complete response
[7-9]. One potential factor in the limited success of these
trials has been the presence of macroscopic or bulky disease
at the time of treatment. Because autologous HCT can
place patients in a minimum disease state, it may represent a
more advantageous clinical setting for adoptive
immunotherapy. Despite the fact that the posttransplanta-
tion period may be marked by deﬁcits in T-cell immunity,
several groups have evaluated the in vitro and in vivo feasi-
bility of immunotherapy following autologous HCT [20].
LAK cells may be generated from PBL and PBPCs of
patients following transplantation [21]. Based upon these
findings, both IL-2 alone and IL-2 with LAK cells have
been administered to patients following autologous trans-
plantation [22,23]. Although the preliminary experience has
been encouraging, the data are too limited to draw firm
conclusions regarding this therapy. Moreover, concerns
about the toxicity and cost of therapy remain [23].
Given the toxicity and marginal efﬁcacy of IL-2 with or
without LAK cells, a more effective form of adoptive
immunotherapy is needed. CIK cells may provide a potent
alternative. Three different models of SCID mice engrafted
with human tumor cells demonstrate in vivo efﬁcacy for CIK
cell–based therapy without the need for systemic coadminis-
tration of IL-2 [13,17,18]. In a model of SCID mice engrafted
with human NHL, CIK cells produced 40% to 50% disease-
free survival at 180 days postinfusion. Polymerase chain
reaction studies in these surviving animals demonstrated no
evidence of residual tumor-speciﬁc chromosomal translocations
such as t(14;18). Conversely, all of the animals treated with
LAK cells died from progressive NHL before 80 days [13].
Previous studies have demonstrated that CD3+CD56+
cells may be expanded from PBL of healthy donors and
from bone marrow and PBPCs of patients with CML
[13,17]. This study extends this experience by demonstrat-
ing that CIK cells may be expanded from G-CSF–mobilized
PBPCs of heavily pretreated patients undergoing apheresis
prior to autologous HCT for a variety of malignancies. The
study group demonstrated a median CD3+CD56+ cell
expansion of 44.8-fold by day 21 and 74.9-fold by day 28.
The maximal degree of CD3+CD56+ cell expansion was
747-fold. The expanded cells demonstrated cytotoxicity
against B-cell lymphoma target cell lines.
In specimens obtained from healthy donors, the maxi-
mal observed expansion of CD3+CD56+ cells has been 1000-
to 6000-fold and the maximal speciﬁc lysis of OCI-Ly8 has
been almost 80% at an effector:target ratio of 40:1 [13,24].
We are unable to draw any conclusions regarding the extent
or etiology of this possible difference between CIK cells
grown from the PBL of healthy donors and those grown
from the mobilized peripheral blood mononuclear cells of
this patient group. Considerable interpatient heterogeneity
was present with respect to disease, prior therapy, and initial
T-cell number at the initiation of cell culture. Therefore, it
is impossible to identify speciﬁc patient variables that corre-
late with more successful CIK cell expansion. Nevertheless,
CD3+CD56+ cells were successfully expanded in the majority
Figure 3. Flow cytometry results of peripheral blood lymphocytes from
patient 2 on day 0 (1A and 1B) and day 44 (2A and 2B) following culture
under cytokine-induced killer cell growth conditions. Plots 1A and 2A
demonstrate an increase in CD3+CD56+ cells from 1.5% to 42.3%, and
plots 1B and 2B demonstrate a decrease in CD13+CD14+ cells from
16.8% to 0.3% over 44 days in culture. In clinical ﬂow cytometry studies,
the patient’s blasts demonstrated staining with CD14 and CD13. FITC
indicates ﬂuorescein isothiocyanate; PE, phycoerythrin.
Figure 4. Speciﬁc lysis of the target B-cell lymphoma cell line, OCI-
Ly8, and autologous leukemic blasts by cytokine-induced killer cells
derived from peripheral blood lymphocytes of 2 patients with acute
myelogenous leukemia. Experiments were performed in triplicate. The
mean values are represented by the points, and 1 standard deviation by
the brackets above and below the points.
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of patients. As in prior studies, the expanded CIK cells
demonstrated significant cytolytic activity against cultured
B-cell lymphoma targets.
The G-CSF–mobilized PBPC product provides an
opportunity for large-scale CIK cell expansion. Mobilized
PBPCs may contain large numbers of T cells for ex vivo cul-
ture and manipulation. One study demonstrated that 106 to
258 × 106 T cells/kg can be collected from G-CSF–mobilized
donors through a 10-liter apheresis procedure [25]. There are
concerns that G-CSF mobilization may have the potential to
alter the proliferative or functional capacity of T cells.
Murine allogeneic transplantation studies using G-CSF–
mobilized stem cells demonstrated that T-cell cytokine
production becomes shifted to a type 2 (humoral/anti-
inﬂammatory) response with increased IL-4 and decreased
IL-2 and IFN-γ synthesis in response to antigenic and mito-
gen stimulation [26]. This phenomenon has also been noted
in G-CSF–mobilized human lymphocytes [27-29].
Despite these hypothetical concerns, a recent phase I
trial has demonstrated the feasibility of large-scale CIK cell
expansion and administration. CIK cells were generated
from steady-state apheresis products of 9 patients with recur-
rent NHL or HD following autologous HCT and cultured
ex vivo in Lifecell bags (Nexell Therapeutics, Irvine, CA).
CD3+ and CD3+CD56+ cell expansion as well as cytotoxicity
were comparable to that demonstrated in this study. Patients
who generated poorly cytolytic effector cells appeared to do
so repetitively. Patients were treated with escalating doses of
CIK cells; the 3 patients in the highest-dose group received a
median of 9.4 × 109 CD3+ cells with minimal infusion-
related toxicity. Two patients achieved a partial response [30].
Although this initial experience is quite encouraging, it is too
early to make a ﬁrm conclusion regarding either the ultimate
efficacy of this form of immunotherapy or the utility of
screening patients for CIK cytolytic activity prior to large-
scale culture.
In this study, cytolytic CIK cells were expanded from
the PBL of 2 patients with active AML. The expanded cells
lysed autologous leukemic blasts. In one of the cultures, an
initially observed cytogenetic abnormality was no longer
present following extended culture. The reduction in malig-
nant cells could have been due to lysis by CIK cells and/or
failure of the leukemic cells to grow under culture condi-
tions that are potentially unfavorable to myeloid cell
growth. Another recent abstract has noted resolution of
leukemia-related cytogenetic abnormalities in clinical sam-
ples obtained from 6 patients following culture of leukemic
peripheral blood under those same culture conditions [31].
Using G-CSF–mobilized PBPCs as precursors, large
numbers of CIK progenitors may be harvested for use in
large-scale expansion systems. This study demonstrates that
PBPC products from patients may be cultured ex vivo to
produce cytolytic effector cells. These effector cells may be
used as a potential means of adoptive immunotherapy in
patients who have achieved a minimal disease state such as
that following autologous HCT.
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